CY1122143T1 - Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα - Google Patents

Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα

Info

Publication number
CY1122143T1
CY1122143T1 CY20191100461T CY191100461T CY1122143T1 CY 1122143 T1 CY1122143 T1 CY 1122143T1 CY 20191100461 T CY20191100461 T CY 20191100461T CY 191100461 T CY191100461 T CY 191100461T CY 1122143 T1 CY1122143 T1 CY 1122143T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
optionally
pi3k
raf
egfr
Prior art date
Application number
CY20191100461T
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Laure Moutouh-De Parseval
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122143(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122143T1 publication Critical patent/CY1122143T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Ένας φαρμακευτικός συνδυασμός που περιλαμβάνει (α) έναν αναστολέα της Β-Raf, (β) έναν αναστολέα του EGFR και προαιρετικά (γ) έναν αναστολέα της ΡΙ3Κ, οι χρήσεις αυτού του συνδυασμού στη θεραπευτική αντιμετώπιση πολλαπλασιαστικών νόσων και μέθοδοι θεραπευτικής αγωγής ενός υποκειμένου που πάσχει από πολλαπλασιαστική νόσο που περιλαμβάνει τη χορήγηση μίας θεραπευτικώς δραστικής ποσότητας αυτού του συνδυασμού.
CY20191100461T 2012-08-07 2019-04-30 Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα CY1122143T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
CY1122143T1 true CY1122143T1 (el) 2020-11-25

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100461T CY1122143T1 (el) 2012-08-07 2019-04-30 Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα

Country Status (39)

Country Link
US (1) US9474754B2 (el)
EP (2) EP2882440B1 (el)
JP (3) JP6342396B2 (el)
KR (1) KR102112885B1 (el)
CN (1) CN104519887B (el)
AR (1) AR092045A1 (el)
AU (1) AU2013299841B8 (el)
CA (1) CA2879548C (el)
CL (1) CL2015000294A1 (el)
CO (1) CO7200273A2 (el)
CY (1) CY1122143T1 (el)
DK (1) DK2882440T3 (el)
EA (1) EA028420B1 (el)
EC (1) ECSP15008695A (el)
ES (1) ES2717911T3 (el)
GT (1) GT201500025A (el)
HK (2) HK1204976A1 (el)
HR (1) HRP20190537T1 (el)
HU (1) HUE042877T2 (el)
IL (1) IL236934B (el)
IN (1) IN2015DN00450A (el)
JO (1) JOP20130236B1 (el)
LT (1) LT2882440T (el)
MA (1) MA37829A1 (el)
MX (1) MX359403B (el)
MY (1) MY176031A (el)
NZ (1) NZ703940A (el)
PE (2) PE20150673A1 (el)
PH (1) PH12015500246A1 (el)
PL (1) PL2882440T3 (el)
PT (1) PT2882440T (el)
RS (1) RS58734B1 (el)
SG (1) SG11201500321YA (el)
SI (1) SI2882440T1 (el)
TN (1) TN2015000027A1 (el)
TR (1) TR201904980T4 (el)
TW (1) TWI607754B (el)
UA (1) UA115786C2 (el)
WO (1) WO2014025688A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
NZ712184A (en) 2013-03-21 2020-01-31 Array Biopharma Inc Combination therapy comprising a b-raf inhibitor and a second inhibitor
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
PL3155126T3 (pl) * 2014-06-16 2019-01-31 Worldwide Innovative Network Sposób wybierania spersonalizowanej terapii potrójnej do leczenia nowotworu
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
WO2017037573A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
UA125436C2 (uk) * 2016-06-03 2022-03-09 Еррей Біофарма, Інк. Фармацевтичні комбінації
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
CA3069564A1 (en) * 2017-08-03 2019-02-07 Novartis Ag Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
EP4364798A2 (en) 2018-10-05 2024-05-08 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
TW202043225A (zh) * 2019-01-25 2020-12-01 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024073364A1 (en) * 2022-09-26 2024-04-04 Beigene, Ltd. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
SG10201402917XA (en) * 2009-08-24 2014-08-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012008519A2 (pt) * 2009-10-12 2016-04-05 Glaxosmithkline Llc combinação
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
JP2013542228A (ja) * 2010-11-08 2013-11-21 ノバルティス アーゲー Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
CN104185631A (zh) 2011-11-10 2014-12-03 纪念斯隆-凯特琳癌症中心 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌
CN103917236A (zh) * 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물

Also Published As

Publication number Publication date
PT2882440T (pt) 2019-04-23
AR092045A1 (es) 2015-03-18
SG11201500321YA (en) 2015-04-29
EA028420B1 (ru) 2017-11-30
JP6974669B2 (ja) 2021-12-01
MA37829A1 (fr) 2017-01-31
ES2717911T3 (es) 2019-06-26
TWI607754B (zh) 2017-12-11
MX359403B (es) 2018-09-26
PE20150673A1 (es) 2015-05-20
KR20150040905A (ko) 2015-04-15
MY176031A (en) 2020-07-22
CL2015000294A1 (es) 2015-05-08
AU2013299841B8 (en) 2017-01-05
US9474754B2 (en) 2016-10-25
EP2882440A1 (en) 2015-06-17
JOP20130236B1 (ar) 2021-08-17
PH12015500246B1 (en) 2015-03-30
MX2015001732A (es) 2015-06-03
JP2018109022A (ja) 2018-07-12
UA115786C2 (uk) 2017-12-26
US20150265616A1 (en) 2015-09-24
AU2013299841A1 (en) 2015-02-12
DK2882440T3 (da) 2019-05-06
AU2013299841B2 (en) 2016-11-24
RS58734B1 (sr) 2019-06-28
EP2882440B1 (en) 2019-02-27
BR112015002384A8 (pt) 2019-07-30
CA2879548A1 (en) 2014-02-13
JP2020019780A (ja) 2020-02-06
JP2015524472A (ja) 2015-08-24
HRP20190537T1 (hr) 2019-06-28
ECSP15008695A (es) 2019-03-29
GT201500025A (es) 2017-09-28
JP6595024B2 (ja) 2019-10-23
KR102112885B1 (ko) 2020-05-19
HUE042877T2 (hu) 2019-07-29
TW201410247A (zh) 2014-03-16
SI2882440T1 (sl) 2019-05-31
EP3574904A1 (en) 2019-12-04
CO7200273A2 (es) 2015-02-27
NZ703940A (en) 2018-04-27
HK1211831A1 (en) 2016-06-03
TR201904980T4 (tr) 2019-05-21
CN104519887A (zh) 2015-04-15
BR112015002384A2 (pt) 2017-07-04
AU2013299841A8 (en) 2017-01-05
PL2882440T3 (pl) 2019-07-31
CA2879548C (en) 2020-07-21
WO2014025688A1 (en) 2014-02-13
LT2882440T (lt) 2019-04-25
PH12015500246A1 (en) 2015-03-30
PE20191655A1 (es) 2019-11-07
IN2015DN00450A (el) 2015-06-26
EA201590332A1 (ru) 2015-06-30
TN2015000027A1 (en) 2016-06-29
CN104519887B (zh) 2017-06-27
JP6342396B2 (ja) 2018-06-13
IL236934B (en) 2018-11-29
HK1204976A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
MX2016008362A (es) Combinaciones farmaceuticas.
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2019006823A (es) Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
CY1126041T1 (el) Σκευασμα φαρμακου για χρηση στον αποτελεσματικο ελεγχο οξεος ή/και χρονιου πονου
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CL2016000170A1 (es) Combinación de oxicodona y naloxona para su uso en el tratamiento del dolor en pacientes que sufren de dolor y una enfermedad que resulta en disbiosis intestinal y/o aumento del riesgo de la translocación bacteriana intestinal.
UA115250C2 (uk) Фармацевтичні комбінації
BR112013019080A2 (pt) métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
AR102494A1 (es) Métodos para tratar enfermedades oculares
CY1121354T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης ή προληψης του ασθματος μεσω χορηγησης ανταγωνιστη il-4r
TH168817A (th) อนุพันธ์อินโดลิซีนซึ่งเป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3-ไคเนส